Key Highlights

  • Commodity Channel index of 158.28 is the highest among the eight names, with RSI at 57.32.
  • Strong buy Moving Average rating sits against a Sell oscillator rating.
  • Up 20.54 per cent over one month, with the highest one-week Volatility of the group at 8.60 per cent.

Technical position

RSI 14 reads 57.32 and the Commodity Channel Index 158.28, the highest of the eight names carrying a positive trend structure. The stochastic sits at 77.95 on %K against 71.62 on %D. Momentum over ten periods at 0.38 and the Awesome Oscillator at 0.22 are among the softer paired readings in the group, which sits at odds with the elevated CCI. The moving average rating reads Strong buy while the oscillator rating reads Sell, one of only two names in the group where the trend and oscillator groups point in opposite directions. The combined technical rating is Buy.

Fundamental snapshot

Prime Medicine sits in health technology with a Market Capitalisation of USD 649.33 million. The shares last traded at USD 3.58, down 3.50 per cent on the session. Trailing Diluted Earnings per Share is negative at USD 1.09, so no price to earnings ratio applies, with earnings per share growth of 32.10 per cent. No Dividend is paid. Analyst consensus reads Strong buy.

Price performance

The stock is up 8.81 per cent over one week, 20.54 per cent over one month and 10.15 per cent over three months, with gains of 2.29 per cent year to date and 1.70 per cent over one year. It is down 15.76 per cent over six months and 81.13 per cent on an all time basis. One week volatility of 8.60 per cent is the highest in the group, with one month volatility at 6.97 per cent.

This article is general information only and does not take into account any individual objectives, financial situation or needs. It is not a recommendation to buy, sell or hold any security. All details are as stated in the company announcement or third party research referenced and are subject to change. Past performance is not a reliable indicator of future performance. Investors should consider the appropriateness of any information having regard to their own circumstances and seek independent financial advice before making any financial decision.